1
|
Mian BM, Feustel PJ, Aziz A, Kaufman RP, Bernstein A, Fisher HAG. Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial. J Urol 2024; 212:21-31. [PMID: 38700844 DOI: 10.1097/ju.0000000000003979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 04/05/2024] [Indexed: 05/05/2024]
Abstract
PURPOSE The comparative effectiveness of transrectal and transperineal prostate biopsy in detecting clinically significant prostate cancer is not well understood. We conducted a randomized clinical trial to determine whether transperineal biopsy improves the detection of clinically significant prostate cancer. MATERIALS AND METHODS Of the 840 men randomized, 93% were White, 44% had a previous biopsy, with a median age of 66 years and median PSA density of 0.14. Of these, 384 underwent transrectal and 398 underwent transperineal prostate biopsy. Prebiopsy prostate MRI was performed in 96% of men. Grade Group ≥ 2 prostate cancer was classified as clinically significant. Odds ratios were calculated using logistic regression to evaluate the effect of biopsy procedures on cancer detection rates. RESULTS The detection rates of clinically significant prostate cancer were 47.1% and 43.2% (odds ratio 1.17; 95% CI, 0.88-1.55) for transrectal and transperineal biopsy, respectively. Age, PSA density, clinical stage and Prostate Imaging Reporting and Data System score were associated with the diagnosis of clinically significant cancer, whereas history of previous biopsy, anterior tumors, and biopsy procedure (transrectal or transperineal) were not. Clinically significant cancer detection rates in biopsy-naïve men undergoing MRI-targeted transrectal or transperineal biopsy were 59% and 62%, respectively. The overall cancer detection rates following transrectal and transperineal biopsy were 72.1% and 70.4%, respectively. CONCLUSIONS There was no significant difference noted in the detection of clinically significant prostate cancer following transrectal or transperineal prostate biopsy. Urologists may utilize either biopsy procedure that best suits their patients' needs and practice setting.
Collapse
|
2
|
Mian BM, Bernstein A, Kaufman RP, Fisher HAG. Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. J Urol 2024; 212:227-228. [PMID: 38728260 DOI: 10.1097/ju.0000000000003975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Accepted: 04/02/2024] [Indexed: 05/12/2024]
|
3
|
Mian BM, Feustel PJ, Aziz A, Kaufman RP, Bernstein A, Fisher HAG. Reply by Authors. J Urol 2024; 212:30-31. [PMID: 38860577 DOI: 10.1097/ju.0000000000004035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Accepted: 05/04/2024] [Indexed: 06/12/2024]
|
4
|
Strother M, Barlotta R, Uzzo R, Bloom E, Jazayeri SB, Bigalli AC, Schober J, Lee J, Bernstein A, Ginsburg K, Handorf E, Chen DY, Correa A, Greenberg R, Smaldone M, Viterbo R, Kutikov A. Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment. Urol Oncol 2024; 42:117.e1-117.e10. [PMID: 38369443 DOI: 10.1016/j.urolonc.2023.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 11/12/2023] [Accepted: 12/11/2023] [Indexed: 02/20/2024]
Abstract
OBJECTIVES To quantitatively describe the nature, severity, and duration of symptoms and functional impairment during recovery from transurethral resection of bladder tumors. MATERIALS AND METHODS All patients scheduled for transurethral resection were approached for enrollment in a text-message based ecological momentary symptom assessment platform. Nine patients reported outcomes were measured 7 days before surgery and on postoperative days 1, 2, 3, 5, 7, 10, and 14 using a 5-point Likert scale. Self-reported degree of hematuria was collected using a visual scale. Clinical data was collected via retrospective chart review. RESULTS A total of 159 patients were analyzed. Postoperative symptoms were overall mild, with the largest differences from baseline to postoperative day 1 seen in dysuria (median 0/5 vs. 3/5) and ability to work (median 5/5 vs. 4/5). Recovery was generally rapid, with 76% of patients reporting ≥4/5 agreement with the statement "I feel recovered from surgery" by postoperative day 2, although 15% of patients reported persistently lower levels of agreement on postoperative day 10 or 14. Patients undergoing larger resections (≥2cm) did take longer to return to baseline in multiple symptom domains, but the difference of medians vs. those undergoing smaller resections was less than 1 day across all domains. Multivariable analysis suggested that receiving perioperative intravesical chemotherapy was associated with longer time to recovery. 84% of patients reported clear yellow urine by postoperative day 3. CONCLUSION In this population, hematuria and negative effects on quality of life resulting from transurethral resection of bladder tumors were generally mild and short-lived, although a small number of patients experienced longer recoveries.
Collapse
|
5
|
Mian BM, Feustel PJ, Aziz A, Kaufman RP, Bernstein A, Avulova S, Fisher HAG. Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. J Urol 2024; 211:205-213. [PMID: 37976319 DOI: 10.1097/ju.0000000000003788] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Accepted: 11/08/2023] [Indexed: 11/19/2023]
Abstract
PURPOSE Transrectal prostate biopsy has come under scrutiny due to potential for postbiopsy infections and transperineal prostate biopsy is being offered as the safer alternative. However, there is a lack of randomized comparative studies. Our goal was to directly evaluate infectious and noninfectious complications following the 2 biopsy procedures. MATERIALS AND METHODS We conducted a prospective, pragmatic, randomized clinical study in men undergoing prostate biopsy. The participants underwent either transrectal or transperineal prostate biopsy in the office under local anesthesia. The primary outcome was a 30-day composite infectious complication rate, comprising of 1 or more components including fever, genitourinary infection, antibiotic prescriptions, office or emergency visits, hospitalization, or sepsis. Secondary outcomes included 30-day composite noninfectious complications (urinary or hemorrhagic). RESULTS Of the 763 randomized participants, 718 underwent either transrectal (351) or transperineal (367) prostate biopsy. A composite infectious complication event occurred in 9 participants (2.6%) in the transrectal and 10 participants (2.7%) in the transperineal group (odds ratio, 1.06; 95% CI, 0.43 to 2.65; P = .99). None of the participants developed sepsis in either group. There were no between-group differences in any of the individual component infectious events. A composite noninfectious complication occurred in 6 (1.7%) and 8 (2.2%) participants in the transrectal and transperineal groups, respectively (odds ratio, 1.28; 95% CI, 0.44 to 3.73; P = .79). No participants required hospitalization or other interventions. CONCLUSIONS Among men undergoing transperineal or transrectal prostate biopsy, we could not demonstrate any difference in the infectious or noninfectious complications. Both biopsy approaches remain clinically viable and safe.
Collapse
|
6
|
Wang X, Lovelace E, Pacheco RR, Pacheco R, Schuster ME, Bernstein A, Akgul M, Lightle A. Atrophic Kidney-Like Lesion-Case Report and Review of the Literature. Int J Surg Pathol 2024:10668969241226703. [PMID: 38291647 DOI: 10.1177/10668969241226703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
Atrophic kidney-like lesion (AKLL) is a rare kidney lesion, which was recently suggested by the Genitourinary Pathology Society as a provisional entity. As of now, 16 examples of AKLL have been described in the literature. Here we report a new tumor which shows similar clinicopathologic characteristics with those previously reported in AKLL. Immunohistochemical (IHC) studies in the current lesion identified a biphasic staining pattern consisting of a mixture of WT1+/KRT7-/PAX8- large dilated cysts and WT-/KRT7+/PAX8+ small atrophic cysts. Histomorphologic features of AKLL overlap with several neoplastic and non-neoplastic entities which can lead to mischaracterization. Awareness of the differentiating features is likely important when evaluating these lesions.
Collapse
|
7
|
Vancavage R, Siddiqui S, Bernstein A, Avulova S. Why has sexuality research in women with bladder cancer undergoing radical cystectomy been ignored for so long? J Sex Med 2023; 20:580-583. [PMID: 37122106 DOI: 10.1093/jsxmed/qdad012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Revised: 01/16/2023] [Accepted: 01/18/2023] [Indexed: 05/02/2023]
|
8
|
Mian BM, Singh Z, Carnes K, Lorenz L, Feustel P, Kaufman RP, Avulova S, Bernstein A, Cangero T, Fisher HAG. Implementation and Assessment of No Opioid Prescription Strategy at Discharge After Major Urologic Cancer Surgery. JAMA Surg 2023; 158:378-385. [PMID: 36753170 PMCID: PMC9909575 DOI: 10.1001/jamasurg.2022.7652] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 10/22/2022] [Indexed: 02/09/2023]
Abstract
Importance Postoperative opioid prescriptions are associated with delayed recovery, perioperative complications, opioid use disorder, and diversion of overprescribed opioids, which places the community at risk of opioid misuse or addiction. Objective To assess a protocol for eliminating postdischarge opioid prescriptions after major urologic cancer surgery. Design, Setting, and Participants This cohort study of the no opioid prescriptions at discharge after surgery (NOPIOIDS) protocol was conducted between May 2017 and June 2021 at a tertiary referral center. Patients undergoing open or minimally invasive radical cystectomy, radical or partial nephrectomy, and radical prostatectomy were sorted into the control group (usual opioids), the lead-in group (reduced opioids), and the NOPIOIDS group (no opioid prescriptions). Interventions The NOPIOIDS group received a preadmission educational handout, postdischarge instructions for using nonopioid analgesics, and no routine opioid prescriptions. The lead-in group received a postdischarge instruction sheet and reduced opioid prescriptions at prescribers' discretion. The control group received opioid prescriptions at prescribers' discretion. Main Outcomes and Measures Primary outcome measures included rate and dose of opioid prescriptions at discharge and for 30 days postdischarge. Additional outcome measures included patient-reported pain and satisfaction level, unplanned health care utilization, and postoperative complications. Results Of 647 opioid-naive patients (mean [SD] age, 63.6 [10.0] years; 478 [73.9%] male; 586 [90.6%] White), the rate of opioid prescriptions at discharge for the control, the lead-in, and the NOPIOIDS groups was 80.9% (157 of 194), 57.9% (55 of 95), and 2.2% (8 of 358) (Kruskal-Wallis test of medians: P < .001), and the overall median (IQR) tablets prescribed was 14 (10-20), 4 (0-5.3), and 0 (0-0) per patient in the control, lead-in, and NOPIOIDS groups, respectively (Kruskal-Wallis test of medians: P < .001). In the NOPIOIDS group, median and mean opioid dose was 0 tablets for all procedure types, with the exception of kidney procedures (mean [SD], 0.5 [1.7] tablets). Patient-reported pain surveys were received from 358 patients (72.6%) in the NOPIOIDS group, demonstrating low pain scores (mean [SD], 2.5 [0.86]) and high satisfaction scores (mean [SD], 86.6 [3.8]). There was no increase in postoperative complications in the group with no opioid prescriptions. Conclusions and Relevance This perioperative protocol, with emphasis on nonopioid alternatives and patient instructions, may be safe and effective in nearly eliminating the need for opioid prescriptions after major abdominopelvic cancer surgery without adversely affecting pain control, complications, or recovery.
Collapse
|
9
|
Talwar R, Bernstein A. AUTHOR REPLY. Urology 2022; 162:26. [DOI: 10.1016/j.urology.2021.07.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Bernstein A, Talwar R, Handorf EA, Syed K, Ginzburg S, Belkoff LH, Reese A, Trabulsi EJ, Jacobs BL, Tomaszewski J, Singer EA, Guzzo TJ, Raman JD, Correa AF. Prostate cancer treatment disparities during the COVID-19 pandemic, lessons from a multi-institutional collaborative. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.6542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6542 Background: Minority communities have been disproportionately affected by COVID-19, however the impact of the pandemic on prostate cancer (PCa) treatment is unknown. To that end, we sought to determine the racial impact on PCa surgery during the first wave of the COVID-19 pandemic. Methods: After receiving institutional review board approval, the Pennsylvania Urologic Regional Collaborative (PURC) database was queried to evaluate practice patterns for Black and White patients with untreated non-metastatic PCa during the initial lockdown of the COVID-19 pandemic (March-May 2020) compared to prior (March-May 2019). PURC is a prospective collaborative, which includes private practice and academic institutions within both urban and rural settings including regional safety-net hospitals. As data entry was likely impacted by the pandemic, we limited our search to only practices that had data entered through June 1, 2020 (5 practice sites). We compared patient and disease characteristics by race using Fisher’s exact and Pearson’s chi-square to compare categorical variables and Wilcoxon rank sum to evaluate continuous covariates. Patients were stratified by risk factors for severe COVID-19 infection as described by the CDC. We determined the covariate-adjusted impact of year and race on surgery, using logistic regression models with a race*year interaction term. Results: 647 men with untreated non-metastatic PCa were identified, 269 during the pandemic and 378 from the year prior. During the pandemic, Black men were significantly less likely to undergo prostatectomy compared to White patients (1.3% v 25.9%;p < 0.001), despite similar COVID-19 risk-factors, biopsy Gleason grade group, and comparable surgery rates prior (17.7% vs. 19.1%;p = 0.75). White men had lower pre-biopsy PSA (7.2 vs. 8.8 vs. p = 0.04) and were older (24.4% vs. 38.2% < 60yr;p = 0.09). The regression model demonstrated an 94% decline in odds of surgery(OR = 0.06 95%CI 0.007-0.43;p = 0.006) for Black patients and increase odds of surgery for White patients (OR = 1.41 95%CI 0.89-2.21;p = 0.142), after adjusting for covariates. Changes in surgical volume varied by site (33% increase to complete shutdown), with sites that experienced the largest reduction in cancer surgery, caring for a greater proportion of Black patients. Conclusions: In a large multi-institutional regional collaborative, odds of PCa surgery declined only among Black patients during the initial wave of the COVID-19 pandemic. While localized prostate cancer does not require immediate treatment, the lessons from this study illuminate systemic inequities within healthcare, likely applicable across oncology. Public health efforts are needed to fully recognize the unintended consequence of diversion of cancer resources to the pandemic in order to develop balanced mitigation strategies as viral rates continue to fluctuate.
Collapse
|
11
|
Akerib D, Alsum S, Araújo H, Bai X, Balajthy J, Baxter A, Bernard E, Bernstein A, Biesiadzinski T, Boulton E, Boxer B, Brás P, Burdin S, Byram D, Carmona-Benitez M, Chan C, Cutter J, de Viveiros L, Druszkiewicz E, Fan A, Fiorucci S, Gaitskell R, Ghag C, Gilchriese M, Gwilliam C, Hall C, Haselschwardt S, Hertel S, Hogan D, Horn M, Huang D, Ignarra C, Jacobsen R, Jahangir O, Ji W, Kamdin K, Kazkaz K, Khaitan D, Korolkova E, Kravitz S, Kudryavtsev V, Leason E, Lenardo B, Lesko K, Liao J, Lin J, Lindote A, Lopes M, Manalaysay A, Mannino R, Marangou N, McKinsey D, Mei DM, Moongweluwan M, Morad J, Murphy A, Naylor A, Nehrkorn C, Nelson H, Neves F, Nilima A, Oliver-Mallory K, Palladino K, Pease E, Riffard Q, Rischbieter G, Rhyne C, Rossiter P, Shaw S, Shutt T, Silva C, Solmaz M, Solovov V, Sorensen P, Sumner T, Szydagis M, Taylor D, Taylor R, Taylor W, Tennyson B, Terman P, Tiedt D, To W, Tvrznikova L, Utku U, Uvarov S, Vacheret A, Velan V, Webb R, White J, Whitis T, Witherell M, Wolfs F, Woodward D, Xu J, Zhang C. Discrimination of electronic recoils from nuclear recoils in two-phase xenon time projection chambers. Int J Clin Exp Med 2020. [DOI: 10.1103/physrevd.102.112002] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
12
|
Li Z, Wystrach L, Bernstein A, Grad S, Alini M, Richards RG, Kubosch D, Südkamp N, Izadpanah K, Kubosch EJ, Lang G. The tissue-renin-angiotensin-system of the human intervertebral disc. Eur Cell Mater 2020; 40:115-132. [PMID: 33006373 DOI: 10.22203/ecm.v040a07] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Symptomatic intervertebral disc (IVD) degeneration accounts for significant socioeconomic burden. Recently, the expression of the tissue renin-angiotensin system (tRAS) in rat and bovine IVD was demonstrated. The major effector of tRAS is angiotensin II (AngII), which participates in proinflammatory pathways. The present study investigated the expression of tRAS in human IVDs, and the correlation between tRAS, inflammation and IVD degeneration. Human IVD tissue was collected during spine surgery and distributed according to principal diagnosis. Gene expression of tRAS components, proinflammatory and catabolic markers in the IVD tissue was assessed. Hydroxyproline (OHP) and glycosaminoglycan (GAG) content in the IVD tissue were determined. Tissue distribution of tRAS components was investigated by immunohistochemistry. Gene expression of tRAS components such as angiotensin-converting enzyme (ACE), Ang II receptor type 2 (AGTR2), angiotensinogen (AGT) and cathepsin D (CTSD) was confirmed in human IVDs. IVD samples that expressed tRAS components (n = 21) revealed significantly higher expression levels of interleukin 6 (IL-6), tumour necrosis factor α (TNF-α), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 and 5 compared to tRAS-negative samples (n = 37). Within tRAS-positive samples, AGT, matrix-metalloproteinases 13 and 3, IL-1, IL-6 and IL-8 were more highly expressed in traumatic compared to degenerated IVDs. Total GAG/DNA content of non-tRAS expressing IVD tissue was significantly higher compared to tRAS positive tissue. Immunohistochemistry confirmed the presence of AngII in the human IVD. The present study identified the existence of tRAS in the human IVD and suggested a correlation between tRAS expression, inflammation and ultimately IVD degeneration.
Collapse
|
13
|
Talwar R, Bernstein A, Jones A, Crook J, Apolo AB, Taylor JM, Burke LM, Plimack ER, Porten SP, Greene KL, Psutka SP, Smith AB. Assessing Contemporary Trends in Female Speakership within Urologic Oncology. Urology 2020; 150:41-46. [PMID: 32798517 DOI: 10.1016/j.urology.2020.08.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 07/21/2020] [Accepted: 08/04/2020] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To evaluate multidisciplinary female representation at urologic oncology conferences, we reviewed speakership trends at contemporary Society of Urologic Oncology (SUO) and American Society of Clinical Oncology Genitourinary Symposium (GU-ASCO) annual meetings. METHODS Meeting programs from SUO and GU-ASCO from 2015 to 2019 were analyzed. Biographical information was determined by querying institutional websites and social/professional media platforms. Statistical analyses were performed to assess for differences and relationships between male and female authorship based on gender, specialty, professional, and educational factors. RESULTS We identified 1102 speakers at genitourinary oncology conferences. Overall, 222 (20%) were female. There was no significant difference between female speakership rates at SUO and GU-ASCO. The overall proportion of female speakers increased over time, but not when analyzing each individual subspecialty conference separately. Several professional and educational differences were noted between genders. Female speakers were more likely to be medical oncologists (P <.001), have more recent years of graduation (2001 vs 1996, P <.001), hold an additional advanced degree (OR 2.09, P = .005), and speak in sessions where other women served as chair (OR 1.42, P = .044). Conversely, female speakers had lower odds of delivering a plenary or keynote address (OR 0.28, P = .015). CONCLUSION We identified a significantly positive trend towards increased female representation within contemporary genitourinary conferences over time; these trends did not remain significant when analyzing each meeting separately. Several important disparities between men and women speakers were identified. Our data suggests that inclusion of women in planning committees may help reduce gender bias and promote diversity within urologic oncology.
Collapse
|
14
|
Rebmann D, Mayr HO, Schmal H, Hernandez Latorre S, Bernstein A. Immunohistochemical analysis of sensory corpuscles in human transplants of the anterior cruciate ligament. J Orthop Surg Res 2020; 15:270. [PMID: 32680550 PMCID: PMC7368668 DOI: 10.1186/s13018-020-01785-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 07/06/2020] [Indexed: 11/12/2022] Open
Abstract
Background Sensory nerve endings in ligaments play an important role for the proprioceptive function. Clinical trials show that the sense of body position does not fully recover in the knee joint after reconstructive surgery of the ruptured anterior cruciate ligament. The aim of this study is to identify sensory corpuscles in autogenous and allogenous transplants of the ligament and to compare their quantity between the used allografts and autografts. Methods Thirty-three patients were included in this study. Three patellar tendon allografts, 14 patellar tendon autografts and 12 semitendinosus autografts were harvested during revision surgery after traumatic rerupture of the graft. The control consisted of 4 healthy anterior cruciate ligaments after fresh rupture. After haematoxylin staining, immunohistochemical analysis was performed using antibodies against S100, p75 and PGP9.5. Microscopical examination was carried out, and the number of mechanoreceptors was counted. Statistical analysis was performed using the Mann-Whitney U test. Results Two types of mechanoreceptors were identified in each graft: Ruffini corpuscles and free nerve endings. The number of Ruffini corpuscles per square centimeter was the highest in the control. Comparing the grafts, the highest number of receptors could be detected in the semitendinosus autograft. The amount of free nerve endings was higher in the semitendinosus and patellar tendon autografts than in the control; the allografts showed the lowest number of receptors. With increasing time after reconstruction, the number of both types of receptors showed a decrease in the semitendinosus graft, whereas it increased in the patellar tendon graft and allograft. The number of mechanoreceptors in the semitendinosus and patellar tendon graft decreased over time after graft-failure, whereas it increased slightly in the allograft. Conclusion This study was the first to identify mechanoreceptors in human transplants of the anterior cruciate ligament. The partial increase in the number of receptors over time after reconstruction could indicate a reinnervation of the grafts.
Collapse
|
15
|
Vargas Amado M, Grütter R, Fischer C, Suter S, Bernstein A. Free-ranging wild boar (Sus scrofa) in Switzerland: casual observations and model-based projections during open and closed season for hunting. SCHWEIZ ARCH TIERH 2020; 162:365-376. [PMID: 32489181 DOI: 10.17236/sat00262] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
INTRODUCTION Wild boar (i.e., Sus scrofa) are susceptible to a range of diseases that can be transmitted to domestic pigs. Assessing the potential risk of transmission-related events involves identifying where wild boar occur in Switzerland and where they still can colonize. It also involves identifying zones where piggeries are dense. In the work presented here, the distribution of wild boar in Switzerland was projected from grid data as probabilities of presence using an approach based on statistical modeling, separately for closed and open season for hunting. The predicted probabilities of wild boar presence were related to the density of piggeries in the six agricultural zones. The resulting maps show how the potential risk of transmission-related events, as a proxy for disease transmission, is distributed in Switzerland. Wild boar presence data consisted of hunting data and casual observations recorded from September 2011 to February 2018 at the coordinate level. They were obtained from all 16 Swiss cantons maintaining a license hunting system plus Solothurn (for 2017) and Zurich, as well as from info fauna. The probability of wild boar occurrence was high (> 0.7) in Jura, the valleys of the Southern Alps, the Rhone Valley down the river from Martigny, and the Rhine Valley down the river from Bündner Herrschaft; it was fair (0.5-0.7) in the Swiss Plateau. These regions broadly overlap agricultural zones with a high density of piggeries. Patches of perennially suitable, but currently not colonized habitat were found in the cantons of Berne, Obwalden, Uri, Schwyz, Glarus, and Grisons. The probability of wild boar occurrence across the entire study area, including the Alps, increased by 12% during closed season for hunting. The results were discussed with reference to similar studies.
Collapse
|
16
|
Lenardo BG, Xu J, Pereverzev S, Akindele OA, Naim D, Kingston J, Bernstein A, Kazkaz K, Tripathi M, Awe C, Li L, Runge J, Hedges S, An P, Barbeau PS. Low-Energy Physics Reach of Xenon Detectors for Nuclear-Recoil-Based Dark Matter and Neutrino Experiments. PHYSICAL REVIEW LETTERS 2019; 123:231106. [PMID: 31868502 DOI: 10.1103/physrevlett.123.231106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 09/17/2019] [Indexed: 06/10/2023]
Abstract
Dual-phase xenon detectors lead the search for keV-scale nuclear recoil signals expected from the scattering of weakly interacting massive particle (WIMP) dark matter, and can potentially be used to study the coherent nuclear scattering of MeV-scale neutrinos. New capabilities of such experiments can be enabled by extending their nuclear recoil searches down to the lowest measurable energy. The response of the liquid xenon target medium to nuclear recoils, however, is not well characterized below a few keV, leading to large uncertainties in projected sensitivities. In this work, we report a new measurement of ionization signals from nuclear recoils in liquid xenon down to the lowest energy reported to date. At 0.3 keV, we find that the average recoil produces approximately one ionization electron; this is the first measurement of nuclear recoil signals at the single-ionization-electron level, approaching the physical limit of liquid xenon ionization detectors. We discuss the implications of these measurements on the physics reach of xenon detectors for nuclear-recoil-based WIMP dark matter searches and the detection of coherent elastic neutrino-nucleus scattering.
Collapse
|
17
|
Akerib DS, Alsum S, Araújo HM, Bai X, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Boxer B, Brás P, Burdin S, Byram D, Carmona-Benitez MC, Chan C, Cutter JE, Davison TJR, Druszkiewicz E, Fallon SR, Fan A, Fiorucci S, Gaitskell RJ, Genovesi J, Ghag C, Gilchriese MGD, Gwilliam C, Hall CR, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Jacobsen RG, Jahangir O, Ji W, Kamdin K, Kazkaz K, Khaitan D, Knoche R, Korolkova EV, Kravitz S, Kudryavtsev VA, Lenardo BG, Lesko KT, Liao J, Lin J, Lindote A, Lopes MI, Manalaysay A, Mannino RL, Marangou N, Marzioni MF, McKinsey DN, Mei DM, Moongweluwan M, Morad JA, Murphy ASJ, Naylor A, Nehrkorn C, Nelson HN, Neves F, Oliver-Mallory KC, Palladino KJ, Pease EK, Riffard Q, Rischbieter GRC, Rhyne C, Rossiter P, Shaw S, Shutt TA, Silva C, Solmaz M, Solovov VN, Sorensen P, Sumner TJ, Szydagis M, Taylor DJ, Taylor WC, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Utku U, Uvarov S, Velan V, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FLH, Woodward D, Xu J, Yazdani K, Zhang C. Results of a Search for Sub-GeV Dark Matter Using 2013 LUX Data. PHYSICAL REVIEW LETTERS 2019; 122:131301. [PMID: 31012624 DOI: 10.1103/physrevlett.122.131301] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 02/12/2019] [Indexed: 06/09/2023]
Abstract
The scattering of dark matter (DM) particles with sub-GeV masses off nuclei is difficult to detect using liquid xenon-based DM search instruments because the energy transfer during nuclear recoils is smaller than the typical detector threshold. However, the tree-level DM-nucleus scattering diagram can be accompanied by simultaneous emission of a bremsstrahlung photon or a so-called "Migdal" electron. These provide an electron recoil component to the experimental signature at higher energies than the corresponding nuclear recoil. The presence of this signature allows liquid xenon detectors to use both the scintillation and the ionization signals in the analysis where the nuclear recoil signal would not be otherwise visible. We report constraints on spin-independent DM-nucleon scattering for DM particles with masses of 0.4-5 GeV/c^{2} using 1.4×10^{4} kg day of search exposure from the 2013 data from the Large Underground Xenon (LUX) experiment for four different classes of mediators. This analysis extends the reach of liquid xenon-based DM search instruments to lower DM masses than has been achieved previously.
Collapse
|
18
|
Krieg P, Killinger A, Gadow R, Burtscher S, Bernstein A. High velocity suspension flame spraying (HVSFS) of metal doped bioceramic coatings. Bioact Mater 2018; 2:162-169. [PMID: 29744426 PMCID: PMC5935181 DOI: 10.1016/j.bioactmat.2017.04.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Revised: 04/19/2017] [Accepted: 04/21/2017] [Indexed: 11/25/2022] Open
Abstract
Bioceramic coatings doped with metals for antibacterial effect. Combination of suspension and precursor flame spraying. Successful deposition of submicron metallic particles in bioceramic matrix.
Collapse
|
19
|
Golan R, Sun T, Bernstein A, Hu J, Sedrakyan A, Kashanian J. PD18-04 EFFECT OF RADIOTHERAPY ON INFLATABLE PENILE PROSTHETIC COMPLICATION AND REOPERATION RATES. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Golan R, Bernstein A, Gu X, Dinerman B, Sedrakyan A, Hu J. MP86-09 INCREASED RESOURCE UTILIZATION IN MEN WITH METASTATIC PROSTATE DOES NOT RESULT IN IMPROVED SURVIVAL OR QUALITY OF LIFE. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Patel NA, Gaffney C, Bernstein A, Sun T, Sedrakyan A, Hu JC. MP59-06 POST-TREATMENT SURVEILLANCE PRACTICE PATTERNS FOR STAGE T1 RENAL CELL CARCINOMA. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. J Urol 2018; 199:1488-1493. [PMID: 29307684 DOI: 10.1016/j.juro.2017.12.058] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2016] [Indexed: 10/18/2022]
Abstract
PURPOSE The accumulation of data through a prospective, multicenter coordinated registry network is a practical way to gather real world evidence on the performance of novel prostate ablation technologies. Urological oncologists, targeted biopsy experts, industry representatives and representatives of the FDA (Food and Drug Administration) convened to discuss the role, feasibility and important data elements of a coordinated registry network to assess new and existing prostate ablation technologies. MATERIALS AND METHODS A multiround Delphi consensus approach was performed which included the opinion of 15 expert urologists, representatives of the FDA and leadership from high intensity focused ultrasound device manufacturers. Stakeholders provided input in 3 consecutive rounds with conference calls following each round to obtain consensus on remaining items. Participants agreed that these elements initially developed for high intensity focused ultrasound are compatible with other prostate ablation technologies. Coordinated registry network elements were reviewed and supplemented with data elements from the FDA common study metrics. RESULTS The working group reached consensus on capturing specific patient demographics, treatment details, oncologic outcomes, functional outcomes and complications. Validated health related quality of life questionnaires were selected to capture patient reported outcomes, including the IIEF-5 (International Index of Erectile Function-5), the I-PSS (International Prostate Symptom Score), the EPIC-26 (Expanded Prostate Cancer Index Composite-26) and the MSHQ-EjD (Male Sexual Health Questionnaire for Ejaculatory Dysfunction). Group consensus was to obtain followup multiparametric magnetic resonance imaging and prostate biopsy approximately 12 months after ablation with additional imaging or biopsy performed as clinically indicated. CONCLUSIONS A national prostate ablation coordinated registry network brings forth vital practice pattern and outcomes data for this emerging treatment paradigm in the United States. Our multiple stakeholder consensus identifies critical elements to evaluate new and existing energy modalities and devices.
Collapse
|
23
|
Faigle G, Bernstein A, Suedkamp NP, Mayr HO, Peters F, Huebner WD, Seidenstuecker M. Release behavior of VAN from four types of CaP-ceramic granules using various loading methods at two different degrees of acidity. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2017; 29:12. [PMID: 29285633 DOI: 10.1007/s10856-017-6006-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 11/17/2017] [Indexed: 06/07/2023]
Abstract
The release behavior of vancomycin (VAN) from beta-tricalciumphosphate (βTCP), hydroxyapatite (HA), glass ceramic (GC) and sponge-like collagen βTCP granule composite (sponge) was studied. Vacuum and drip loading methods were compared. The influence of VAN concentration and pH on release behavior was analyzed with respect to a stable release level of VAN above the minimum inhibitory concentration over 14 days. Initially the morphology of the granule carrier systems was examined with ESEM, stereomicroscopy, µCT-imaging and Camsizer® regarding porosity, interconnecting pores and granule size. Drug release patterns following a vacuum and a drip loading method with VAN at concentrations of 5 and 50 mg/ml were compared. The influence of pH 7.4 compared to pH 5.0 on release behavior was studied. The drug was released in bidistilled water at 37 °C, the concentration determined by photometry at 220 nm. For statistical purposes, the mean and standard deviation were calculated and analyzed by Origin 9.1 Professional SR1 (OriginLab). Due to low interconnectivity and low porosity, the vacuum loading method was unable to attain complete drug loading of the ceramic granules. The sponge showed an inhomogeneous distribution of βTCP granules. Drug release was high at pH 7.4, at pH 5.0 it practically did not occur. All samples except for the collagen-complex show an initial VAN burst release with a following steady release. Loading with 5 mg/ml concentrated VAN resulted in a higher percentage of available drug being released. However, when loaded with 50 mg/ml, the absolute amount of drug released was higher.
Collapse
|
24
|
Akerib DS, Alsum S, Aquino C, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Brás P, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJR, Dobi A, Dobson JEY, Druszkiewicz E, Edwards BN, Faham CH, Fallon SR, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gibson KR, Gilchriese MGD, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Jacobsen RG, Ji W, Kamdin K, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy ASJ, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Palladino KJ, Pease EK, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solmaz M, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor WC, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Velan V, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FLH, Xu J, Yazdani K, Young SK, Zhang C. First Searches for Axions and Axionlike Particles with the LUX Experiment. PHYSICAL REVIEW LETTERS 2017; 118:261301. [PMID: 28707937 DOI: 10.1103/physrevlett.118.261301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Indexed: 06/07/2023]
Abstract
The first searches for axions and axionlike particles with the Large Underground Xenon experiment are presented. Under the assumption of an axioelectric interaction in xenon, the coupling constant between axions and electrons g_{Ae} is tested using data collected in 2013 with an exposure totaling 95 live days ×118 kg. A double-sided, profile likelihood ratio statistic test excludes g_{Ae} larger than 3.5×10^{-12} (90% C.L.) for solar axions. Assuming the Dine-Fischler-Srednicki-Zhitnitsky theoretical description, the upper limit in coupling corresponds to an upper limit on axion mass of 0.12 eV/c^{2}, while for the Kim-Shifman-Vainshtein-Zhakharov description masses above 36.6 eV/c^{2} are excluded. For galactic axionlike particles, values of g_{Ae} larger than 4.2×10^{-13} are excluded for particle masses in the range 1-16 keV/c^{2}. These are the most stringent constraints to date for these interactions.
Collapse
|
25
|
Akerib DS, Alsum S, Araújo HM, Bai X, Bailey AJ, Balajthy J, Beltrame P, Bernard EP, Bernstein A, Biesiadzinski TP, Boulton EM, Brás P, Byram D, Cahn SB, Carmona-Benitez MC, Chan C, Chiller AA, Chiller C, Currie A, Cutter JE, Davison TJR, Dobi A, Dobson JEY, Druszkiewicz E, Edwards BN, Faham CH, Fallon SR, Fiorucci S, Gaitskell RJ, Gehman VM, Ghag C, Gilchriese MGD, Hall CR, Hanhardt M, Haselschwardt SJ, Hertel SA, Hogan DP, Horn M, Huang DQ, Ignarra CM, Jacobsen RG, Ji W, Kamdin K, Kazkaz K, Khaitan D, Knoche R, Larsen NA, Lee C, Lenardo BG, Lesko KT, Lindote A, Lopes MI, Manalaysay A, Mannino RL, Marzioni MF, McKinsey DN, Mei DM, Mock J, Moongweluwan M, Morad JA, Murphy ASJ, Nehrkorn C, Nelson HN, Neves F, O'Sullivan K, Oliver-Mallory KC, Palladino KJ, Pease EK, Reichhart L, Rhyne C, Shaw S, Shutt TA, Silva C, Solmaz M, Solovov VN, Sorensen P, Stephenson S, Sumner TJ, Szydagis M, Taylor DJ, Taylor WC, Tennyson BP, Terman PA, Tiedt DR, To WH, Tripathi M, Tvrznikova L, Uvarov S, Velan V, Verbus JR, Webb RC, White JT, Whitis TJ, Witherell MS, Wolfs FLH, Xu J, Yazdani K, Young SK, Zhang C. Limits on Spin-Dependent WIMP-Nucleon Cross Section Obtained from the Complete LUX Exposure. PHYSICAL REVIEW LETTERS 2017; 118:251302. [PMID: 28696768 DOI: 10.1103/physrevlett.118.251302] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Indexed: 06/07/2023]
Abstract
We present experimental constraints on the spin-dependent WIMP-nucleon elastic cross sections from the total 129.5 kg yr exposure acquired by the Large Underground Xenon experiment (LUX), operating at the Sanford Underground Research Facility in Lead, South Dakota (USA). A profile likelihood ratio analysis allows 90% C.L. upper limits to be set on the WIMP-neutron (WIMP-proton) cross section of σ_{n}=1.6×10^{-41} cm^{2} (σ_{p}=5×10^{-40} cm^{2}) at 35 GeV c^{-2}, almost a sixfold improvement over the previous LUX spin-dependent results. The spin-dependent WIMP-neutron limit is the most sensitive constraint to date.
Collapse
|